# Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

> **NCT01903278** · PHASE3 · COMPLETED · sponsor: **Beijing Kawin Technology Share-Holding Co., Ltd.** · enrollment: 719 (actual)

## Conditions studied

- Chronic Hepatitis c

## Interventions

- **DRUG:** PEG-IFN-SA /RBV
- **DRUG:** Pegasys /RBV

## Key facts

- **NCT ID:** NCT01903278
- **Lead sponsor:** Beijing Kawin Technology Share-Holding Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 719 (ACTUAL)
- **Last updated:** 2015-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903278, "Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01903278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*